Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mitobronitol SCHEMBL23128365 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL10047597 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL8500 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitobronitol SCHEMBL24408845 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| Mitolactol SCHEMBL8455 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL3798965 | 0.87 | ALDH1A1 (0.75) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL8648464 | 0.84 | ALDH1A1 (0.71) | ALDH1A1LMNAL3MBTL1TDP1 | |
| SCHEMBL561011 | 0.82 | — | — | |
| SCHEMBL10837948 | 0.82 | — | — | |
| SCHEMBL4421089 | 0.78 | ALDH1A1 (0.60) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 36523 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260085100-A1 | METHODS OF ANTIGEN PRODUCTION | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2026-03-26 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-12576077-B2 | Composition for preventing, alleviating or treating cancer | CKP THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| CN-1261803-A | Antioxidant enhancement of therapy for hyperproliferative conditions | ATHEROGENICS INC (US) | 2000-08-02 | — | — | CN | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999042578-A2 | MODULATION OF CELL PROLIFERATION, METHODS AND REAGENTS | COLD SPRING HARBOR LABORATORY (US) | 1999-08-26 | — | — | WO | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |